Product Overview
CJC-1295 with DAC: Sustained Natural Growth Hormone Support
Why CJC-1295 with DAC is of special interest to patients: Declining GH with age contributes to slower recovery, increased fat, and reduced muscle tone. This long-acting analog provides convenient, steady support for body composition, repair, and vitality while mimicking your body’s own rhythm.
Potential Benefits Shown in Early Limited Evaluations Early research (pre-clinical and human PK/PD studies) has shown:
- Prolonged elevations in GH and IGF-1 with once-weekly dosing.
- Improved body composition markers in exploratory settings.
- Good tolerability with physiologic (not supraphysiologic) GH release. These are from smaller or early-phase evaluations.
- Noted:CJC-1295 with Dac has been stated to be stacked with other peptides. Possibly these stacks may provide for potential enhanced results depending on research indication of interest. These finding are limited and should be researched more fully in human studies for safety and efficacy. Human clinical data remains limited, and it is not FDA-approved for therapeutic use primarily researched or used off-label/investigationally.
CJC-1295 with DAC is a modified 30-amino-acid analog of growth-hormone-releasing hormone (GHRH).
It is a synthetic long-acting version of the natural hormone your hypothalamus produces to stimulate growth hormone (GH) pulses.
How it works (Mechanism of Action): The Drug Affinity Complex (DAC) binds to albumin, dramatically extending half-life. It selectively stimulates the pituitary to release natural GH in sustained yet physiologic pulses—without disrupting other hormones.
Why CJC-1295 with DAC is of special interest to patients: Declining GH with age contributes to slower recovery, increased fat, and reduced muscle tone. This long-acting analog provides convenient, steady support for body composition, repair, and vitality while mimicking your body’s own rhythm.
Potential Benefits Shown in Early Limited Evaluations Early research (pre-clinical and human PK/PD studies) has shown:
- Prolonged elevations in GH and IGF-1 with once-weekly dosing.
- Improved body composition markers in exploratory settings.
- Good tolerability with physiologic (not supraphysiologic) GH release. These are from smaller or early-phase evaluations.
- Noted:CJC-1295 with Dac has been stated to be stacked with other peptides. Possibly these stacks may provide for potential enhanced results depending on research indication of interest. These finding are limited and should be researched more fully in human studies for safety and efficacy. Human clinical data remains limited, and it is not FDA-approved for therapeutic use primarily researched or used off-label/investigationally.
Backed by science:
- Pre-clinical studies in pituitary cell cultures and animals confirmed the DAC modification extends duration of GH release while preserving natural pulsatility.
- Clinical data in healthy adults demonstrated single doses produce sustained, dose-dependent GH and IGF-1 increases lasting several days with excellent safety.